Drug:
Reaction: WRONG TECHNIQUE IN PRODUCT USAGE PROCESS
20260101 - 20261231
No. 1 - 100
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 1 | 26555364 |
US |
80 | 2 |
Wrong technique in product usage process, Carpal tunnel decompression, Trigger finger, Muscular weakness, |
||||
EVOLOCUMAB, |
||||
| 2 | 26555390 |
US |
2 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 3 | 26555391 |
US |
1 | |
Wrong technique in device usage process, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 4 | 26555433 |
US |
83 | 2 |
Wrong technique in product usage process, Injection site erythema, |
||||
EVOLOCUMAB, |
||||
| 5 | 26555521 |
US |
82 | 2 |
Nausea, Dizziness, Balance disorder, Incorrect dose administered, Product physical issue, Wrong technique in product usage process, |
||||
DIGOXIN, |
||||
| 6 | 26555859 |
US |
13 | |
Acute myeloid leukaemia recurrent, Wrong technique in product usage process, |
||||
VENETOCLAX, |
||||
| 7 | 26555942 |
US |
2 | |
Injection site pain, Fatigue, Wrong technique in product usage process, Injection site pain, |
||||
LANREOTIDE ACETATE, |
||||
| 8 | 26556194 |
US |
2 | |
Wrong technique in product usage process, Expired product administered, |
||||
NIRAPARIB, |
||||
| 9 | 26556596 |
US |
||
Facial asymmetry, Wrong technique in product usage process, Off label use, |
||||
PRABOTULINUM TOXIN TYPE A, |
||||
| 10 | 26556688 |
CA |
63 | 2 |
Alopecia, Application site reaction, Chronic spontaneous urticaria, Depression, Dyspnoea, Dyspnoea exertional, Haemorrhage, Headache, Hepatic enzyme increased, Urticaria, Tachycardia, Insomnia, Intervertebral disc protrusion, Malaise, Middle insomnia, Muscular weakness, Pain, Paraesthesia, Primary biliary cholangitis, Pruritus, Scratch, Skin burning sensation, Skin lesion, Skin plaque, Spinal meningeal cyst, Stress, Erythema, Product dose omission issue, Drug ineffective, Incorrect dose administered, Inappropriate schedule of product administration, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, OMALIZUMAB, NICOTINE, NICOTINE POLACRILEX, NICOTINE POLACRILEX MINI, NICOTINE POLARILEX, |
||||
| 11 | 26556936 |
US |
||
Wrong technique in product usage process, Product use complaint, |
||||
NIRAPARIB, |
||||
| 12 | 26557078 |
EU |
1 | |
Drug intolerance, Product use in unapproved indication, Wrong technique in product usage process, |
||||
ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, ARIPIPRAZOLE, |
||||
| 13 | 26557145 |
EU |
56 | 2 |
Phlebitis superficial, Paraesthesia oral, Faeces pale, Dysphagia, Wrong technique in product usage process, |
||||
| 14 | 26557325 |
GB |
||
Wrong technique in product usage process, Product use complaint, |
||||
ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, |
||||
| 15 | 26558585 |
EG |
156 | 1 |
Acidosis, Blood gases abnormal, Hyperglycaemia, Device issue, Device failure, Drug dose omission by device, Device mechanical issue, Device issue, Product storage error, Wrong technique in product usage process, Product knowledge deficit, |
||||
INSULIN DEGLUDEC, |
||||
| 16 | 26558849 |
BR |
44 | 2 |
Device leakage, Incorrect dose administered by device, Wrong technique in product usage process, Off label use, |
||||
SEMAGLUTIDE, SEMAGLUTIDE, BUPROPION, DESVENLAFAXINE, DESVENLAFAXINE SUCCINATE, |
||||
| 17 | 26558963 |
US |
6 | 1 |
Product use issue, Wrong technique in product usage process, |
||||
SORAFENIB, SORAFENIB, CISPLATIN, DEXRAZOXANE FOR INJECTION, DEXRAZOXANE, DOXORUBICIN, |
||||
| 18 | 26559143 |
US |
13 | 1 |
Wheezing, Urticaria, Paraesthesia oral, Therapy cessation, Product administration error, Wrong technique in product usage process, |
||||
CETIRIZINE HYDROCHLORIDE, EPINEPHRINE, ADRENALINUM, |
||||
| 19 | 26559381 |
TH |
47 | 1 |
Hallucination, auditory, Hypomania, Irritability, Wrong technique in product usage process, |
||||
LURASIDONE HYDROCHLORIDE, SERTRALINE, LEMBOREXANT, LEMBOREXANT, CLONAZEPAM, |
||||
| 20 | 26559488 |
JP |
1 | |
Death, Wrong technique in product usage process, |
||||
BEMPEDOIC ACID, |
||||
| 21 | 26559518 |
JP |
70 | 1 |
Renal impairment, Myelosuppression, Rash, Wrong technique in product usage process, Therapy cessation, |
||||
BEMPEDOIC ACID, EZETIMIBE, ROSUVASTATIN, ROSUVASTATIN, |
||||
| 22 | 26559901 |
US |
2 | |
Pain, Wrong technique in product usage process, Psoriasis, |
||||
RISANKIZUMAB-RZAA, |
||||
| 23 | 26560311 |
EU |
1 | |
Oesophageal stenosis, Metastases to oesophagus, Thyroid cancer, Malignant neoplasm progression, Dysphagia, Wrong technique in product usage process, |
||||
TRAMETINIB, DABRAFENIB, |
||||
| 24 | 26560491 |
80 | ||
Migraine, Pain, Hot flush, Vision blurred, Paraesthesia, Wrong technique in product usage process, |
||||
| 25 | 26560993 |
US |
2 | |
Cardiac operation, Wrong technique in product usage process, |
||||
SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 26 | 26561311 |
1 | ||
Diabetic ketoacidosis, Wrong technique in product usage process, |
||||
INSULIN LISPRO, INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 27 | 26550803 |
US |
80 | 2 |
Blister, Product package associated injury, Product dose omission in error, Wrong technique in product usage process, Product closure removal difficult, |
||||
LATANOPROST, LATANOPROST, |
||||
| 28 | 26550805 |
US |
2 | |
Eye irritation, Drug ineffective, Circumstance or information capable of leading to medication error, Wrong technique in product usage process, |
||||
LIFITEGRAST, LIFITEGRAST, PERFLUOROHEXYLOCTANE, |
||||
| 29 | 26551154 |
US |
2 | |
Wrong technique in product usage process, Incorrect dose administered, |
||||
FAMOTIDINE, |
||||
| 30 | 26551165 |
US |
69 | 1 |
Wrong technique in product usage process, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 31 | 26551403 |
HK |
8 | 1 |
Eyelid function disorder, Epistaxis, Wrong technique in product usage process, |
||||
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, ARIPIPRAZOLE, |
||||
| 32 | 26551455 |
US |
36 | 2 |
Injection site haemorrhage, Injury associated with device, Wrong technique in product usage process, Device difficult to use, Device use error, |
||||
EVOLOCUMAB, EVOLOCUMAB, EVOLOCUMAB, |
||||
| 33 | 26551722 |
US |
||
Incorrect dose administered, Expired product administered, Wrong technique in product usage process, |
||||
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE, |
||||
| 34 | 26551731 |
US |
2 | |
Eye pruritus, Vision blurred, Product delivery mechanism issue, Wrong technique in product usage process, Prescribed underdose, Inappropriate schedule of product administration, Product leakage, |
||||
PERFLUOROHEXYLOCTANE, PERFLUOROHEXYLOCTANE, |
||||
| 35 | 26552221 |
US |
2 | |
Blister, Product closure removal difficult, Product dose omission in error, Wrong technique in product usage process, |
||||
LATANOPROST, LATANOPROST, |
||||
| 36 | 26552402 |
US |
63 | 1 |
Wrong technique in device usage process, Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, VITAMIN C, |
||||
| 37 | 26552633 |
74 | 1 | |
Urine abnormality, Wrong technique in product usage process, |
||||
POLYETHYLENE GLYCOL 3350, OXYCODONE HYDROCHLORIDE, OXYCODONE, MORPHINE SULFATE, |
||||
| 38 | 26552945 |
GB |
1 | |
Colitis ulcerative, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 39 | 26553011 |
US |
||
Drug effect less than expected, Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 40 | 26553012 |
US |
||
Incorrect product administration duration, Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 41 | 26553018 |
US |
1 | |
Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 42 | 26553019 |
US |
||
Hypotension, Hypertension, Feeling abnormal, Drug interaction, Product use in unapproved indication, Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 43 | 26553022 |
US |
||
Wrong technique in product usage process, Underdose, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 44 | 26553035 |
US |
81 | 1 |
Choking sensation, Gingival swelling, Gingival discomfort, Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 45 | 26553066 |
US |
92 | 2 |
Choking sensation, Oropharyngeal discomfort, Retching, Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 46 | 26553123 |
US |
||
Wrong technique in product usage process, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, |
||||
| 47 | 26553145 |
EU |
61 | 2 |
Gamma-glutamyltransferase increased, Wrong technique in product usage process, |
||||
SEMAGLUTIDE, |
||||
| 48 | 26553588 |
AU |
86 | 1 |
Discomfort, Emotional distress, Peritoneal dialysis complication, Wrong technique in product usage process, Increased intraperitoneal volume, |
||||
| 49 | 26553685 |
2 | ||
Wrong technique in product usage process, |
||||
| 50 | 26553737 |
EU |
40 | 2 |
Peripheral swelling, Temperature intolerance, Angiopathy, Erythema, Pruritus, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE HEMIHYDRATE, PAROXETINE, PAROXETINE HYDROCHLORIDE, |
||||
| 51 | 26553863 |
US |
2 | |
Headache, Inappropriate schedule of product administration, Wrong technique in product usage process, Incorrect dose administered, Product dose omission issue, |
||||
FREMANEZUMAB-VFRM, FREMANEZUMAB-VFRM, |
||||
| 52 | 26553933 |
US |
63 | 2 |
Wrong technique in product usage process, |
||||
BELATACEPT, |
||||
| 53 | 26554013 |
US |
1 | |
Dyspnoea, Incorrect product administration duration, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
ENSIFENTRINE, ENSIFENTRINE, PATIROMER, |
||||
| 54 | 26554048 |
US |
67 | 2 |
Injection site reaction, Wrong technique in product usage process, Incorrect dose administered, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 55 | 26554456 |
US |
64 | 2 |
Injection site pain, Wrong technique in product usage process, Incorrect dose administered, |
||||
TIRZEPATIDE, TIRZEPATIDE, |
||||
| 56 | 26554639 |
US |
1 | |
Spinal operation, Arthralgia, Myalgia, Product residue present, Wrong technique in product usage process, Product use in unapproved indication, Dysphonia, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 57 | 26555084 |
42 | 2 | |
Injury associated with device, Wrong technique in product usage process, Needle issue, Off label use, Product physical issue, |
||||
ARIPIPRAZOLE LAUROXIL, |
||||
| 58 | 26548879 |
US |
1 | |
Wrong technique in device usage process, Wrong technique in product usage process, Product complaint, |
||||
FLUTICASONE FUROATE, |
||||
| 59 | 26548881 |
US |
2 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 60 | 26548890 |
US |
2 | |
Wrong technique in device usage process, Wrong technique in product usage process, Product dose omission issue, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 61 | 26548938 |
US |
1 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 62 | 26549027 |
US |
2 | |
Wrong technique in product usage process, Product complaint, |
||||
ALBUTEROL SULFATE, |
||||
| 63 | 26549062 |
US |
1 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 64 | 26549104 |
US |
78 | 1 |
Complication associated with device, Product dose omission issue, Wrong technique in product usage process, |
||||
GEMCITABINE INTRAVESICAL, GEMCITABINE INTRAVESICAL, |
||||
| 65 | 26549658 |
US |
66 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
DUPILUMAB, |
||||
| 66 | 26549740 |
US |
77 | 2 |
Incorrect dose administered, Wrong technique in product usage process, Diarrhoea, Nausea, |
||||
TIRZEPATIDE, |
||||
| 67 | 26549825 |
34 | 2 | |
Needle issue, Wrong technique in product usage process, |
||||
NALTREXONE, NALTREXONE, NALTREXONE, HYDROXYZINE, ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, BUPROPION, MELATONIN, ERGOCALCIFEROL, |
||||
| 68 | 26549828 |
44 | 1 | |
Needle issue, Wrong technique in product usage process, |
||||
NALTREXONE, |
||||
| 69 | 26549853 |
36 | 1 | |
Needle issue, Wrong technique in product usage process, |
||||
NALTREXONE, GABAPENTIN, KETOCONAZOLE, KETOCONAZOLE FOAM, KETOCONAZOLE CREAM, 2%, VILAZODONE HYDROCHLORIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ERGOCALCIFEROL, NITROGLYCERIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ATORVASTATIN CALCIUM, |
||||
| 70 | 26546809 |
US |
2 | |
Hot flush, Product adhesion issue, Wrong technique in product usage process, |
||||
ESTRADIOL, |
||||
| 71 | 26546988 |
US |
||
Wrong technique in product usage process, Product packaging quantity issue, |
||||
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE, |
||||
| 72 | 26547072 |
US |
2 | |
Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
INSULIN GLARGINE, |
||||
| 73 | 26547143 |
US |
2 | |
Wrong technique in product usage process, Eye swelling, Lacrimation increased, Ocular discomfort, Eye irritation, Ocular hyperaemia, Eye pain, Conjunctivitis, |
||||
OLOPATADINE HYDROCHLORIDE, POLYETHYLENE GLYCOL 400 AND PROPYLENE GLYCOL, |
||||
| 74 | 26547246 |
US |
74 | 2 |
Neoplasm malignant, Product container issue, Wrong technique in product usage process, |
||||
CARBOXYMETHYLCELLULOSE SODIUM, |
||||
| 75 | 26547297 |
US |
2 | |
Middle insomnia, Muscle disorder, Tendonitis, Blood oestrogen decreased, Hot flush, Weight increased, Rash, Product adhesion issue, Product residue present, Intentional product use issue, Wrong technique in product usage process, |
||||
ESTRADIOL, ESTRADIOL, |
||||
| 76 | 26547308 |
US |
||
Intercepted product preparation error, Wrong technique in product usage process, Device leakage, Product packaging issue, |
||||
LEUPROLIDE ACETATE, |
||||
| 77 | 26547320 |
US |
89 | 2 |
Product packaging quantity issue, Liquid product physical issue, Poor quality product administered, Wrong technique in product usage process, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE, |
||||
| 78 | 26547373 |
US |
2 | |
Poor quality product administered, Product container issue, Product contamination, Wrong technique in product usage process, |
||||
CARBOXYMETHYLCELLULOSE SODIUM AND GLYCERIN, |
||||
| 79 | 26547454 |
US |
1 | |
Wrong technique in product usage process, Incorrect dose administered, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TIOTROPIUM BROMIDE INHALATION SPRAY, ERGOCALCIFEROL, NINTEDANIB, OXYGEN, 0XYGEN, LORATADINE, LORATADINE ORAL, GUAIFENESIN, |
||||
| 80 | 26547479 |
US |
2 | |
Palpitations, Sleep disorder, Night sweats, Hot flush, Intermenstrual bleeding, Skin discolouration, Patient dissatisfaction with treatment, Wrong technique in product usage process, Product adhesion issue, |
||||
ESTRADIOL, PROGESTERONE, ACETAMINOPHEN, ASPRIN, CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID) AND CAFFEINE, ACETAMINOPHEN, ASPIRIN (NSAID), AND CAFFEINE, ACETAMINOPHEN, ACETAMINOPHEN, ASPIRIN, AND CAFFEINE, ACETAMINOPHEN, CAFFEINE, ONABOTULINUMTOXINA, |
||||
| 81 | 26547551 |
US |
2 | |
Wrong technique in product usage process, Product adhesion issue, |
||||
ESTRADIOL, ESTRADIOL, |
||||
| 82 | 26547571 |
US |
1 | |
Product size issue, Product label issue, Wrong technique in product usage process, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 83 | 26547764 |
US |
1 | |
Wrong technique in product usage process, Injection site discharge, |
||||
ADALIMUMAB, |
||||
| 84 | 26547803 |
US |
2 | |
Product adhesion issue, Wrong technique in product usage process, No adverse event, |
||||
ESTRADIOL, |
||||
| 85 | 26548316 |
US |
83 | 2 |
Product use complaint, Wrong technique in product usage process, Product closure removal difficult, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 86 | 26548317 |
US |
77 | 2 |
Product package associated injury, Product container seal issue, Product closure removal difficult, Wrong technique in product usage process, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 87 | 26548318 |
US |
2 | |
Product closure removal difficult, Wrong technique in product usage process, Product package associated injury, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 88 | 26548322 |
US |
89 | 2 |
Product packaging quantity issue, Liquid product physical issue, Poor quality product administered, Wrong technique in product usage process, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE, |
||||
| 89 | 26548352 |
US |
||
Mood swings, Brain fog, Blood oestrogen decreased, Nausea, Hot flush, Irritability, Insomnia, Night sweats, Arthralgia, Alopecia, Vulvovaginal dryness, Pain, Bladder dysfunction, Product adhesion issue, Product adhesion issue, Wrong technique in product usage process, Product quality issue, |
||||
ESTRADIOL, |
||||
| 90 | 26548456 |
|||
Accidental exposure to product, Wrong technique in product usage process, Needle issue, Device issue, |
||||
BIMEKIZUMAB, |
||||
| 91 | 26542139 |
US |
71 | 2 |
Bowel movement irregularity, Incorrect dose administered, Wrong technique in product usage process, |
||||
LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, |
||||
| 92 | 26542303 |
US |
2 | |
Product adhesion issue, Wrong technique in product usage process, Circumstance or information capable of leading to medication error, |
||||
NICOTINE TRANSDERMAL SYSTEM PATCH, |
||||
| 93 | 26542427 |
US |
2 | |
Myalgia, Joint instability, Incorrect dose administered, Wrong technique in product usage process, Weight bearing difficulty, Tremor, Muscle spasms, |
||||
BEMPEDOIC ACID, BEMPEDOIC ACID, |
||||
| 94 | 26542461 |
US |
2 | |
Anxiety, Attention deficit hyperactivity disorder, Irritability, Arthralgia, Neck pain, Quality of life decreased, Feeling abnormal, Product dose omission in error, Wrong technique in product usage process, Inappropriate schedule of product administration, Back pain, Pain in extremity, |
||||
BEMPEDOIC ACID, BEMPEDOIC ACID, BEMPEDOIC ACID, ALPRAZOLAM, POTASSIUM CHLORIDE, LANSOPRAZOLE, METHOCARBAMOL, METHOCARBAMOL TABLETS, |
||||
| 95 | 26542478 |
US |
2 | |
Wrong technique in product usage process, Intentional underdose, |
||||
BEMPEDOIC ACID, |
||||
| 96 | 26542488 |
US |
2 | |
Vein disorder, Wrong technique in product usage process, Adverse drug reaction, Muscle spasms, |
||||
BEMPEDOIC ACID, BEMPEDOIC ACID, MAGNESIUM, |
||||
| 97 | 26542507 |
US |
2 | |
Wrong technique in product usage process, |
||||
BEMPEDOIC ACID, BEMPEDOIC ACID, |
||||
| 98 | 26542510 |
US |
2 | |
Headache, Dyspnoea, Wrong technique in product usage process, Inappropriate schedule of product administration, |
||||
BEMPEDOIC ACID, |
||||
| 99 | 26542745 |
US |
2 | |
Wrong technique in product usage process, |
||||
ALBUTEROL SULFATE, |
||||
| 100 | 26543188 |
US |
||
Alopecia, Application site reaction, Chronic spontaneous urticaria, Depression, Dyspnoea, Haemorrhage, Headache, Hepatic enzyme increased, Tachycardia, Insomnia, Intervertebral disc protrusion, Malaise, Paraesthesia, Primary biliary cholangitis, Pruritus, Scratch, Skin burning sensation, Skin lesion, Skin plaque, Spinal meningeal cyst, Stress, Erythema, Product dose omission issue, Drug ineffective, Incorrect dose administered, Inappropriate schedule of product administration, Wrong technique in product usage process, |
||||
OMALIZUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28